Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Tevimbra (tislelizumab) for the treatment of patients with esophageal, gastroesophageal junction, and gastric cancer
- Tevimbra (tislelizumab) for the treatment of patients with esophageal, gastroesophageal junction, and gastric cancer in the first line in combination with ChT with expression
- Polpril Plus (ramiprilum + indapamidum) for the treatment of hypertension as replacement therapy in adult patients whose blood pressure is adequately controlled with ramipril and indapamide in the same doses as in the combination product, but in separate medicinal products
- Pemazyre (pemigatinibum) for the treatment of patients with hepatocellular carcinoma or bile duct cancer
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
